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The use of an in vitro colony-forming assay has previously led to identification of a mesoderm-derived bipo-
tent hemangioblast from differentiating hESCs. In this issue of Cell Stem Cell, Vodyanik et al. have used
a similar approach to herald the presence of a bipotent mesoderm-derived precursor for mesenchymal
stem and endothelial cells, termed the mesenchymoangioblast.Given the vast differentiation potential
of mouse and human embryonic stem
cells (ESCs), defining specific pathways
of lineage specification could be daunt-
ing. However, this process has steadily
been enhanced through application of
the knowledge of developmental cues
gleaned from the study of model organ-
isms. During gastrulation, the emergence
of the primary germ layers (ectoderm,
mesoderm, and endoderm) presages
a critical stage in embryonic development
that has been well studied. A variety of
tools have been required to identify
specific differentiated cell types emerging
from the three germ layers, including
genetic knockin/reporter ESC lines to
follow lineage differentiation in culture,
monoclonal antibodies and flow cytome-
try to purify differentiated progeny, and
derivation of colony-forming assays that
permit examination of clonal precursor-
progeny relationships. Modification of
standard hematopoietic progenitor col-
ony-forming assays permitted the identifi-
cation of the hemangioblast, a bipotent
precursor cell present in mouse ESC-
derived embryoid bodies. The hemangio-
blast formed blast colonies in semisolid
medium and gave rise to hematopoietic
and endothelial progeny (Choi et al.,
1998). In vivo identification of a compa-
rable progenitor was later confirmed in
the posterior primitive streak of early
mouse embryos (Huber et al., 2004).
Similar colony-forming assays have sub-
sequently beenmodified to identify meso-
derm-derived hematopoietic progeny
from hESCs.
In this issue of Cell Stem Cell, Vodyanik
et al. (2010) employed a colony-forming
assay to identify an hESC mesoderm-
derived common precursor for mesen-chymal stem/stromal cells (MSCs) and
endothelial cells. MSCs are somatic
cells present in many connective tissues
throughout the body and are largely
defined in vitro by adherence to tissue
culture plastic; extensive proliferative
potential; expression of the cell surface
markers CD73, CD90, CD105, and
CD146; and multilineage differentiation
into bone, cartilage, adipose, and con-
nective tissues (Caplan, 2007). While
MSCs are known to originate from neural
crest and mesoderm precursors during
embryogenesis and have been isolated
from hESC and induced pluripotent stem
cells (iPSCs) (Lee et al., 2007; Trivedi
and Hematti, 2007), the direct meso-
dermal precursor of the MSCs in pluripo-
tent stem cell cultures has not been well
defined.
To identify MSC precursors of meso-
dermal origin, Vodyanik et al. (2010)
cocultured hESCs with mouse OP9
stromal cells under conditions known to
promote mesendodermal differentiation.
The authors then plated the dif-
ferentiating hESC in serum-free semisolid
medium in the presence of FGF2 to assay
for colony-forming activity. The authors
found that hESCs cocultured for 2 days
gave rise to unique tightly packed
spheroid colonies upon plating that were
morphologically distinct from the blast
colonies that emerged from hESCs that
had been cocultured for 3 days. Both
types of colonies were transient and could
not be grown from hESCs that had been
cocultured for 4 or more days prior to
plating. In contrast to the blast colonies
that flourished in the presence of VEGF
and FGF2, growth of the compact colo-
nies was inhibited by the addition of
VEGF. Both types of colonies could alsoCell Stem Cell 7,
STEM 824_823be grown from iPSC/OP9 cocultures,
though the method used for iPSC deriva-
tion was a major determinant for suc-
cess. Continued growth of the compact
spheres for 12 days permitted iden-
tification of a uniform population of
cells expressing mesenchymal markers
CD140a, CD90, CD56, CD166, and
CD146, but not hematopoietic or endo-
thelial markers CD43, CD45, or CD31,
prompting the authors to name the
compact colonies mesenchymal (MS)
colonies. Using time-lapse photography
and single-cell deposition approaches,
the authors confirmed the clonal origin of
the MS colonies. To assess their differen-
tiation potential, the authors grew the MS
colonies on OP9 cells and found that
although amajority of the cells maintained
the CD146-expressing MSC phenotype,
a small proportion expressed endothelial
markers. When the authors grew the MS
colonies on Matrigel-coated dishes, they
found that endothelial cells migrated out
of the colonies and formed capillary-like
tubular structures consistent with an
endothelial lineage commitment. The
authors concluded from these experi-
ments that the precursor cells giving rise
to theMS colonies possessmesenchymal
and endothelial lineage potential and
named this precursor the mesenchy-
moangioblast. Single isolated MS colo-
nies could be robustly expanded on
collagen/fibronectin-coated dishes and
a majority of these MSC lines displayed
multilineage potential for bone, cartilage,
and adipose cells.
Further studies identified apelin
receptor APLNR (or angiotensin receptor
like-1)-expressing cells derived from
hESCs cocultured on OP9 cells as en-
riched for mesoderm-specific transcriptsDecember 3, 2010 ª2010 Elsevier Inc. 643
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embryonic mesoderm. Fractionation of
APLNR+ or APLNR cellular subsets de-
monstrated that essentially all the precur-
sors for both blast and MS colonies were
present in the APLNR+ fraction, though
the MS colonies were minimally enriched
by the selection. Additional work demon-
strated that the antibody used in the
APLNR+ cell selection was inhibitory to
MS colony growth (potentially explaining
the lack of MS colony enrichment
following cell sorting). A final set of studies
defined the stages at which the APLNR+
mesoderm cells generated core formation
of both MS and blast colonies and re-
vealed that the endothelial program was
only temporally active in both types of
colonies. Further maturation of MS colo-
nies was associated with progressive
loss of endothelial potential and an
increase in mesenchymal potential.
As with most innovative work, many
more questions arise than were resolved
as we survey the new information pro-
vided in this report (Vodyanik et al.,
2010). First, although the MS colonies
appear to be derived from APLNR+meso-
derm, at present, no unique marker has
been identified to prospectively isolate
and enrich the mesenchymoangioblast
precursor of the MS colonies. The identifi-
cation of the MS colonies within serum-
free semisolid medium is an important
tool that will permit screening of potential
markers for this unique precursor cell
and may also assist in determining
whether the mesenchymoangioblast re-
sides within or upstream of other recently
reported hESC-derived mesodermal644 Cell Stem Cell 7, December 3, 2010 ª20subsets (Davis et al., 2008; Evseenko
et al., 2010). Second, one wonders
whether the endothelial cells derived
from the MS colonies are similar in func-
tion to those derived from the blast colo-
nies, and what these findings might tell
us about the developmental origin of this
bipotent mesoderm subset. Recent
evidence indicates that endothelial cells
are the first cell type to emerge in the
murine blast colony and that the hemato-
poietic cells produced within the colony
are born directly from hemogenic endo-
thelial cells (Lancrin et al., 2009; Eilken
et al., 2009). Since endothelial potential
appears early in the MS colonies, one
may wonder whether a similar endothelial
to mesenchymal transition may be at
work in the emergence of the mesen-
chymal cells within the MS colonies.
Vodyanik et al. (2010) point out that
MSCs emerging from hESC-derived
neural crest cells are known to be deriva-
tives of the neuroepithelium. Thus, deriva-
tion of MSCs from mesoderm-derived
endothelium would be a remarkable
outcome that may highlight a distinctive
paradigm of mesodermal differentiation
into several cell lineages (blood, MSC)
from pluripotent stem cells via hemogenic
or mesenchymogenic endothelial inter-
mediates. Though hemogenic endothelial
cells have been identified within the
developing mouse embryo, mesenchy-
mogenic cells represent a putative popu-
lation that should be pursued. Finally,
MSCs derived from human bone marrow
have been tested in clinical trials for the
treatment of graft-versus-host disease in
patients that have received a hematopoi-10 Elsevier Inc.
STEM 824_823etic stem cell transplant, a decrease in in-
flammation in treatment-resistant Crohn’s
disease, and asmeans to repair damaged
bone and cartilage. Comparing the
phenotype and function of the hESC-
derived MSC populations will be impor-
tant to assess whether they display similar
properties to primary bone marrow-
derived MSC when tested in preclinical
models of graft-versus-host disease,
intestinal inflammation, and bone and
cartilage repair.
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